ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 173 filers reported holding ACCELERON PHARMA INC in Q3 2018. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $608,718 | +32.8% | 3,537 | -3.2% | 0.01% | +50.0% |
Q2 2021 | $458,415 | -5.4% | 3,653 | +2.2% | 0.01% | -14.3% |
Q1 2021 | $484,535 | +1.6% | 3,573 | -4.2% | 0.01% | 0.0% |
Q4 2020 | $477,088 | +11.5% | 3,729 | -1.9% | 0.01% | 0.0% |
Q3 2020 | $427,839 | +28.9% | 3,802 | +9.1% | 0.01% | +16.7% |
Q2 2020 | $332,016 | -72.5% | 3,485 | -74.1% | 0.01% | -76.9% |
Q1 2020 | $1,207,673 | +63.1% | 13,438 | -3.8% | 0.03% | +116.7% |
Q4 2019 | $740,477 | +31.2% | 13,966 | -2.3% | 0.01% | +20.0% |
Q3 2019 | $564,598 | -1.6% | 14,290 | +2.3% | 0.01% | 0.0% |
Q2 2019 | $573,600 | -11.8% | 13,963 | 0.0% | 0.01% | -16.7% |
Q1 2019 | $650,257 | +20.4% | 13,963 | +12.6% | 0.01% | +9.1% |
Q4 2018 | $540,020 | -22.9% | 12,400 | +1.4% | 0.01% | -15.4% |
Q3 2018 | $700,152 | -99.9% | 12,234 | 0.0% | 0.01% | +30.0% |
Q2 2018 | $593,594,000 | +24.1% | 12,234 | 0.0% | 0.01% | +42.9% |
Q1 2018 | $478,349,000 | +94063.2% | 12,234 | +2.2% | 0.01% | 0.0% |
Q4 2017 | $508,000 | -69.2% | 11,968 | -72.9% | 0.01% | -30.0% |
Q3 2017 | $1,648,000 | +145.6% | 44,164 | +100.0% | 0.01% | +100.0% |
Q2 2017 | $671,000 | +25.4% | 22,082 | +9.2% | 0.01% | +25.0% |
Q1 2017 | $535,000 | +3.7% | 20,217 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $516,000 | -29.5% | 20,217 | 0.0% | 0.00% | -20.0% |
Q3 2016 | $732,000 | +6.6% | 20,217 | 0.0% | 0.01% | 0.0% |
Q2 2016 | $687,000 | +41.6% | 20,217 | +10.1% | 0.01% | +25.0% |
Q1 2016 | $485,000 | -36.0% | 18,367 | +18.1% | 0.00% | -33.3% |
Q4 2015 | $758,000 | +95.9% | 15,546 | 0.0% | 0.01% | +100.0% |
Q3 2015 | $387,000 | -22.8% | 15,546 | -1.9% | 0.00% | -25.0% |
Q2 2015 | $501,000 | +1.4% | 15,844 | +22.0% | 0.00% | 0.0% |
Q1 2015 | $494,000 | -2.4% | 12,985 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $506,000 | +28.8% | 12,985 | 0.0% | 0.00% | +33.3% |
Q3 2014 | $393,000 | -10.9% | 12,985 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $441,000 | +137.1% | 12,985 | +141.3% | 0.00% | +200.0% |
Q1 2014 | $186,000 | -44.3% | 5,382 | -36.2% | 0.00% | -50.0% |
Q4 2013 | $334,000 | – | 8,439 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |